[Ziprasidone. A new second-generation antipsychotic agent].
Lublin
Henrik K
HK
H:S Rigshospitalet, Psykiatrisk Afdeling O. hlublin@rh.dk
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007273:Injections, Intramuscular; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D010879:Piperazines; D012702:Serotonin Antagonists; D013844:Thiazoles; C092292:ziprasidone